|
3.3 中心性浆液性脉络膜视网膜病变
Jose等研究发现：PDT治疗中心性浆液性脉络膜视网膜病变，能提高最佳矫正视力、减少视网膜下积液、使黄斑中心凹的厚度边薄，没有1例出现严重的视力下降及并发症[31]。Michele等比较了用标准量[32]：50J/cm2与低量：25J/cm2的光照治疗中心性浆液性脉络膜视网膜病变的疗效，结果发现：在大多数患者，两组视力都能随视网膜下积液的吸收而提高，但在低量组，脉络膜灌注不足的发生率低于标准量组，且产生的副作用更小。除了上诉疾病外，PDT还用于眼睑增生性血管瘤[33]、眼睑乳头状瘤[34]等眼科疾病的治疗，也可应用于睫状体消融[35]等治疗领域。
4 小结
PDT作为一种新的治疗方法为肿瘤及其它疾病的治疗开创了一个全新的局面。在眼科疾病方面，PDT因其安全、有效、副作用少而受到越来越多的重视。随着第二代光敏剂的发展，我们相信，PDT将逐渐取代一些传统的方法，而应用于更多疾病的治疗。
【参考文献】
1 Moghissi K, Dixon K, Stringer M, et al. Photofrin PDT for early stage oesophageal cancer: long term results in 40 patients and literature review. Photodiagnosis Photodyn Therapy 2009;6(34):159166
2 Maarten AM Wildeman, Heike J Nyst, Baris Karakullukcu, et al. Photodynamic therapy in the therapy for recurrent/ persistent nasopharyngeal cancer. Head and Neck Oncology 2009;1(1):40
3 Samkoe KS, Chen A, Rizvi I, et al. Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int J Radiat Oncol Biol Phys 2010;76(1):251259
4 FanjulVélez F, SalasGarcia I, OrtegaQuijano N, et al. Photochemical approach of photodynamic therapy applied to skin. Conf Proc IEEE Eng Med Biol Soc 2009;1:278281
5 Stukavec J, Horak L, Duchac V, et al. Comparison of photodynamic therapy with phthalocyanine and photofrin in human colorectal carcinoma. Neoplasma 2008;55(2):127129
6 Saczko J, Skrzypek W, Chwikowska A, et al. Photooxidative action in cervix carcinoma cells induced by HPD mediated photodynamic therapy. Exp Oncol 2009;31(4):195199
7 Tang PM, Zhang DM, Xuan NH, et al. Photodynamic therapy inhibits Pglycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbidea. Mol Cancer 2009;31(8):56
8 Muller PJ, Wilson BC. Photodynamic therapy of brain tumorsa work in progress. Lasers Surg Med 2006;38(5):384389
9 Zawislak A, Donnelly RF, McCluggage WG, et al. Clinical and immunohistochemical assessment of vulval intraepithelial neoplasia following photodynamic therapy using a novel bioadhesive patchtype system loaded with 5aminolevulinic acid. Photodiagnosis Photodyn Ther 2009;6(1):2840
10 Panjehpour M, Coppola D, Overholt BF, et al. Photodynamic therapy of Barrett's esophagus: ablation of Barretts mucosa and reduction in p53 protein expression after treatment. Anticancer Res 2008;28(1B):485489
11 顾瑛,刘凡光,王开，等.光动力疗法治疗鲜红斑痣1216例临床分析.中国激光医学杂志 2001;10(2):8689
12 Zhu TC, Finlay JC.The role of photodynamic therapy (PDT) physics. Med Phys 2008;35(7):31273136
13 Wyld L, Reed MW, Brown NJ. Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer 2001;84(10):13841386
14 Huang Z, Chen Q, Luck D, et al. Studies of a vascularacting photosensitizer, Pdbacteriopheophorbide(Tookad),in normal canine prostate and spontaneous canine prostate cancer. Lasers Surg Med 2005;36(5):390397
15 车宁，封宇飞，傅得兴,等.维替泊芬的药理和临床应用.中国新药杂志2005;6(14):785787
16 陈文晖.光动力治疗药物5氨基酮戊酸的研究进展.中国激光医学杂志 2005;14(6):375384
17 于丽，李晓原.第二代光敏剂血卟啉单甲醚及其临床应用研究进展.生物医学工程与临床 2005;11(6):365368
18 黄正，强永刚，陈伟.光动力学疗法诱导抗肿瘤免疫反应研究的进展.中国激光医学杂志 2006;4(2):121124
19 Jurklies B, Bornfeld N. The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma. Graefes Arch Clin Exp Ophthalmol 2005;243(5):393396
20 Honda S, Kurimoto Y, Kagotani Y, et al. Photodynamic therapy for typical agerelated macular degeneration and polypoidal choroidal vasculopathy: a 30month multicenter study in Hyogo, Japan. Jpn J Ophthalmol 2009;53(6):593597
21 Baba T, KubotaTaniai M, Kitahashi M, et al.Twoyear comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br J Ophthalmol 2009;Epub ahead of print
22 王凯，姜燕荣，黎晓新,等.引起黄斑下脉络膜新生血管的几种常见疾病的光相干断层扫描图像特征分析.中华眼底病杂志 2005;21(2):6973
23 Verteporfin Roundtable 2000 and 2001 Participants. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to agerelated macular degeneration and other causes. Retina 2002;22(1):618
24 Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to agerelated macular degeneration and other causes: update. Retina 2005;25(2):119134
25 Barbazetto IA, Lee TC, Abramson DH. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am J Ophthalmol 2005;139(4):759760
26 Puccioni M, Santoro N, Giansanti F, et al. Photodynamic therapy using methyl aminolevulinate acid in eyelid basal cell carcinoma: a 5year followup study. Ophthal Plast Reconstr Surg 2009;25(2):115118
27 Singh AD, Kaiser PK,Sears JE, et al. Photodynamic therapy of circumscribed choroidal haemangioma. Br J Ophthalmol 2004;88(11):14141418
28 Huang S, Fabian J, Murray T, et al. Symptomatic circumscribed choroidal hemangioma undergoing PDT: VA outcomes. Optom Vis Sci 2009;86(3):286289
29 Jurklies B, Bornfeld N. The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma. Graefes Arch Clin Exp Ophthalmol 2005;243(5):393396
30 Stephan H, Boeloeni R, Eggert A, et al. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2008;49(7):31583163
31 RuizMoreno JM, Lugo FL, Armadá F, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 2009;27(11):16
32 Reibaldi M, Cardascia N, Longo A, et al. Standardfluence versus lowfluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010;149(2):307315
33 Sanchez CG, Caballero Chávez YV, Plazola S. Photodynamic therapy for palpebral and conjunctival proliferative vascular tumors: clinical case report. Orbit 2009;28(6):420421
34 Dai T, Huang YY, Hamblin MR. Photodynamic therapy for localized infectionsstate of the art. Photodiagnosis Photodyn Ther 2009;6(34):170188
35 Rivellese MJ, Baumal CR. Photodynamic therapy of eye diseases. J Ophthalmic Nurs Technol 2000;19(3):134141 上一页 [1] [2] |
